Pieris stock deflates as AstraZeneca stops trials of asthma drug in response to toxicology...

[cafead]

via AstraZeneca has pulled the plug on clinical trials of its asthma candidate elarekibep after seeing data from a toxicology study. Pieris Pharmaceuticals, which licensed the inhaled IL-4 receptor alpha inhibitor to AstraZeneca, attributed the decision to “lung findings” from a 13-week nonclinical assessment.

article source